Breakdown | TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 19.32B | 20.36B | 26.40B | 33.91B | 32.81B | 20.51B |
Gross Profit | 15.33B | 16.10B | 19.24B | 26.63B | 26.43B | 16.48B |
EBITDA | 16.50M | -627.00M | -432.24M | 2.67B | 4.71B | 1.68B |
Net Income | -1.03B | -1.48B | -733.97M | 1.42B | 2.79B | 1.14B |
Balance Sheet | ||||||
Total Assets | 11.16B | 11.00B | 12.14B | 12.30B | 13.07B | 6.85B |
Cash, Cash Equivalents and Short-Term Investments | 5.06B | 4.76B | 4.67B | 2.97B | 6.06B | 1.90B |
Total Debt | 2.06B | 2.44B | 2.26B | 1.41B | 911.41M | 1.99B |
Total Liabilities | 4.63B | 4.88B | 4.53B | 3.95B | 6.17B | 5.40B |
Stockholders Equity | 6.54B | 6.12B | 7.61B | 8.35B | 6.90B | 1.45B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | -395.00M | 1.64B | -3.53B | 2.68B | 196.34M |
Operating Cash Flow | 0.00 | 425.00M | 2.42B | -3.32B | 2.75B | 338.23M |
Investing Cash Flow | 0.00 | -540.00M | -900.97M | -297.68M | -180.83M | -135.76M |
Financing Cash Flow | 0.00 | 183.00M | 179.77M | 501.62M | 1.58B | 979.68M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | ¥11.43B | 55.71 | 2.11% | 4.75% | -83.63% | ||
69 Neutral | ¥7.83B | 10.65 | ― | -17.95% | ― | ||
68 Neutral | €7.72B | 15.81 | 12.45% | 2.53% | 2.04% | 4.27% | |
62 Neutral | ¥9.57B | 10,315.80 | 0.57% | 16.15% | 19.02% | ||
61 Neutral | ¥6.19B | 10.74 | 2.44% | -2.13% | ― | ||
52 Neutral | ¥7.22B | 176.82 | 1.33% | -7.66% | ― | ||
45 Neutral | ¥4.82B | 35.38 | 1.78% | 0.10% | -239.09% |
Premier Anti-Aging Co., Ltd. has revised its full-year consolidated earnings forecast for the fiscal year ending July 31, 2025, due to mixed performance across its business segments. While the recovery business through subsidiary Venex Co., Ltd. showed strong sales, the anti-aging segment underperformed, leading to an overall reduction in expected net sales. Despite this, operating profit exceeded expectations due to reduced advertising expenses and effective cost management. The company plans to invest in marketing for its renewed ‘DUO’ brand and new ‘Lalaskin’ skincare line, while remaining cautious about the challenging business environment, particularly in the Chinese market.
Premier Anti-Aging Co., Ltd. reported a decrease in net sales and operating profits for the first nine months of the fiscal year ending July 31, 2025, compared to the previous year. Despite the decline in sales, the company achieved a profit attributable to owners of the parent, indicating a recovery from the previous year’s losses. The company has revised its earnings forecasts for the full fiscal year, suggesting a cautious yet optimistic outlook for future performance.